Finding the best marijuana stocks in the stock market today may be easier than you think. At one time, it was a simple task to determine which cannabis companies were better to invest in. Even with the sector's many ups and downs and constant issues with momentum, the sector is still on the rise. In 2026, there is much to look forward to that could not only push the industry forward but also turn a profit for shareholders.

NASDAQ | TSX: ACB As a leading global medical cannabis company, advancements in breeding, testing and production trials for powdery mildew-resistant cultivars reinforce Aurora's leadership in cannabis science EDMONTON, AB, Jan. 14, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce significant progress in its powdery mildew (PM) resistance research, nearly one year after the company's breakthrough discovery of a novel source of genetic resistance against powdery mildew, PM2. Since the initial discovery, Aurora has performed multiple rounds of crosses to transfer PM2 resistance into elite breeding lines.

Bankers have argued that Pot Inc.'s far-bigger prospective business – recreational use that would include the smoking of joints and ingesting high-inducing gummies – wasn't specifically addressed by the president's edict.

Aurora Cannabis faces uneven gains from marijuana reclassification as medical cannabis drives growth, while weak consumer sales affect optimism.

The cannabis industry continues evolving into a bigger and more regulated global market. Legalization trends are expanding across the United States and international regions. This growth fuels long-term opportunities for marijuana stock investors and those looking to get invested in the industry. Cannabis stocks benefit from increasing consumer demand and acceptance. Medical cannabis adoption supports consistent revenue and defensive market positioning.

President Trump has ordered that marijuana be reclassified as a Schedule III drug. The move doesn't fully legalize marijuana -- yet -- but it may foreshadow changes to come.

The cannabis industry is entering another critical growth phase, positioning 2026 as a potentially pivotal year. Particularly for long-term investors looking to make a profit with marijuana stocks. After years of regulatory uncertainty, capital constraints, and volatile price action, relief is being shown. The legal cannabis market is showing clear signs of structural improvement driven by policy reform, consolidation, and expanding global demand.

In 2026, the impact of cannabis rescheduling is expected to be far more visible in marijuana stock performance. Much more than in the initial announcement of cannabis becoming a Class 3 substance. While 2025 seemed to be a transition year, 2026 could mark another pivot point. Specifically, one where improved business operations begin to consistently translate into stronger equity valuations across the sector. Investor sentiment may also shift meaningfully.

President Donald Trump's marijuana reclassification executive order followed a yearlong push by cannabis executives, billionaire allies and political operatives combining donations, lobbying and targeted polling, according to industry insiders. Trulieve CEO Kim Rivers and Palm Beach billionaire Howard Kessler leveraged personal ties, fundraisers and political spending to press the White House, according to multiple insiders, including one CEO of a cannabis company listed on the New York Stock Exchange, who requested anonymity to speak candidly.

As On The Money has been reporting since April, our famously drug-and-drink-averse president has been inching ever closer to making marijuana significantly less criminal in the eyes of the federal government.